INDIAN BENCHMARK upbeat to begin with. Tata Power's board will deliberate on various fund raising options, including by way of preferential issue of shares to institutional investors, on February 27.
FURTHER, Ranbaxy Labs will be in focus after Japanese drugmaker Daiichi Sankyo Co Ltd said that its Indian unit Ranbaxy Laboratories Ltd has suspended shipment of pharmaceutical ingredients produced at its Toansa and Dewas plants. JP Associates may be in action on reports of stake sale of cement plants.
Trend in FII flows: The FIIs were net buyers of Rs.266cr in the cash segment on Monday while the domestic institutional investors (DIIs) were net sellers of Rs. 248cr, as per the provisional figures released by the NSE.